New Study Continues to Validate Nuvilex's Approach to Medical Marijuana Research
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 10/22/13 -- Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., received another validation of their efforts to bring research utilizing cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer to the industry. This latest study serves as another piece of evidence in a mounting argument that cannabinoids from Cannabis, such as CBD, are effective anti-cancer drugs.
It was a team at St George's, University of London that provided the latest data which was published in the journal Anticancer Research. Dr. Wai Liu and his colleagues carried out laboratory investigations that used a number of cannabinoids, either alone or in combination with each other, to measure their anti-cancer actions in relation to leukemia.
The team studied six cannabinoids and each demonstrated anti-cancer properties as effective as those seen with tetrahydrocannabinol (THC), and, of note, they found the cannabinoids had an increased effect on cancer cells when combined with each other.
This group's research has shown that the non-hallucinogenic components of Cannabis can act as effective anti-cancer agents. The anti-cancer properties of THC, the primary hallucinogenic component of Cannabis, have been recognized for many years, but research into similar Cannabis-derived compounds has been somewhat limited.
Dr Liu who led the team of researchers said, "This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.
These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own."
Nuvilex established Medical Marijuana Sciences to study the medical applications of marijuana and will use its expertise, current research and its success in the biotechnology sector in an effort to make the subsidiary among the leaders in the industry.
Continue Reading:
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information:
Contact:
Stock Market Media Group
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.10.2013 - 12:45 Uhr
Sprache: Deutsch
News-ID 308034
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Study Continues to Validate Nuvilex's Approach to Medical Marijuana Research"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvilex, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
